These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36152731)

  • 1. CD93 promotes acute myeloid leukemia development and is a potential therapeutic target.
    Jia J; Liu B; Wang D; Wang X; Song L; Ren Y; Guo Z; Ma K; Cui C
    Exp Cell Res; 2022 Nov; 420(2):113361. PubMed ID: 36152731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis.
    Han H; Liu J; Zhu S; Zhao T
    J Cell Mol Med; 2024 Jul; 28(14):e18552. PubMed ID: 39054581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
    Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
    Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
    Richards RM; Zhao F; Freitas KA; Parker KR; Xu P; Fan A; Sotillo E; Daugaard M; Oo HZ; Liu J; Hong WJ; Sorensen PH; Chang HY; Satpathy AT; Majzner RG; Majeti R; Mackall CL
    Blood Cancer Discov; 2021 Nov; 2(6):648-665. PubMed ID: 34778803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD93 a potential player in cytotrophoblast and endothelial cell migration.
    Fantone S; Tossetta G; Di Simone N; Tersigni C; Scambia G; Marcheggiani F; Giannubilo SR; Marzioni D
    Cell Tissue Res; 2022 Jan; 387(1):123-130. PubMed ID: 34674045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
    Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
    J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.
    Nativel B; Ramin-Mangata S; Mevizou R; Figuester A; Andries J; Iwema T; Ikewaki N; Gasque P; Viranaïcken W
    Immunology; 2019 Oct; 158(2):85-93. PubMed ID: 31335975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of CD93 cell surface expression by protein kinase C isoenzymes.
    Ikewaki N; Kulski JK; Inoko H
    Microbiol Immunol; 2006; 50(2):93-103. PubMed ID: 16490927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
    Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A
    Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometric identification of CD93 expression on naive T lymphocytes (CD4(+)CD45RA (+) cells) in human neonatal umbilical cord blood.
    Ikewaki N; Yamao H; Kulski JK; Inoko H
    J Clin Immunol; 2010 Sep; 30(5):723-33. PubMed ID: 20512406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insight into CD93 recognition by IGFBP7.
    Xu Y; Sun Y; Zhu Y; Song G
    Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells.
    Barbera S; Raucci L; Tassone G; Tinti L; Prischi F; Santucci A; Mongiat M; Tosi GM; Galvagni F; Dimberg A; Pozzi C; Orlandini M
    Int J Biol Macromol; 2023 Jan; 224():453-464. PubMed ID: 36265539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
    Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
    Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.
    Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL
    PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma.
    Bao L; Tang M; Zhang Q; You B; Shan Y; Shi S; Li L; Hu S; You Y
    Biochem Biophys Res Commun; 2016 Aug; 476(4):467-474. PubMed ID: 27255994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble expression of disulfide-bonded C-type lectin like domain of human CD93 in the cytoplasm of Escherichia coli.
    Nativel B; Figuester A; Andries J; Planesse C; Couprie J; Gasque P; Viranaicken W; Iwema T
    J Immunol Methods; 2016 Dec; 439():67-73. PubMed ID: 27742562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis.
    Griffiths MR; Botto M; Morgan BP; Neal JW; Gasque P
    Immunology; 2018 Nov; 155(3):346-355. PubMed ID: 29923617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.
    Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M
    Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
    Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
    Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.